Ethicon told the Full Federal Court on Monday that the judge overseeing the marathon class action against it over allegedly defective vaginal mesh devices got it wrong when she reset the dates for inclusion in the class.
Pharmaceutical and life sciences giant Bayer is facing a potential class action in Australia over its birth control device Essure, which can allegedly cause nickel poisoning and other severe complications.
Consumer goods giant Reckitt Benckiser has been ordered by the Federal Court to remove all in-store advertising for its Strepfen throat lozenges after a successful interlocutory application by rival iNova Pharmaceuticals.
Ophthalmic diagnostic device manufacture ObjectiVision can’t file amended claims for damages following a trial in a copyright and contract case against the University of Sydney, with a judge saying the school would be “severely prejudiced” if the new claims were allowed.
Ophthalmic diagnostic device maker ObjectiVision’s amended claims for damages, filed after a 25-day patent hearing, are “outlandish” and “unfair,” the University of Sydney has told the Federal Court.
The final day of trial in the ACCC’s case over muscle gel Voltaren wrapped up Wednesday with a barrister for GlaxoSmithKline slamming as ‘onerous’ a compliance regime proposed by the consumer watchdog and blasting an injunction as unnecessary for a problem the pharmaceutical giant ‘inherited’ from Novartis.
The first day of a liability hearing in a consumer case over GlaxoSmithKline’s marketing for its popular Voltaren products has seen an ACCC witness deflect accusations the regulator was vague about its misleading packaging concerns, placing the blame squarely on the pharmaceutical giant.
Two generic drug makers have lost their bid for confidential documents related to Neurim Pharmaceuticals’ patents covering sleep drug Circadin, with a court ruling legal professional privilege was waived in a phone conversation between a DLA Piper lawyer and the company’s founder.
A former executive of hospital operator Healthe Care Pty has been charged with three counts of insider trading, the Australian Securities and Investments Commission said Monday.
The ACCC has brought a cartel case against biologics company Cryosite for agreeing to coordinate with competitor Cell Care prior to the completion of their merger agreement.